The global Small-molecule Respiratory Drug market was valued at US$ 42153 million in 2025 and is anticipated to reach US$ 65244 million by 2032, at a CAGR of 6.5% from 2026 to 2032.

Small-molecule Respiratory Drug Market

Small-molecule respiratory drugs are prescription medicines whose active ingredients are low-molecular-weight chemicals used to prevent or treat airway and lung diseases such as asthma, COPD, allergic airway conditions, and cystic fibrosis. Therapeutic strategies typically combine bronchodilation, anti-inflammation, and microenvironment control (mucus/airway physiology). Key mechanisms include β2-agonists and muscarinic antagonists, inhaled corticosteroids, leukotriene-pathway inhibitors, PDE inhibitors, and—within select indications—disease-modifying small molecules targeting CFTR. Delivery is predominantly inhaled (MDI/DPI/nebulization), complemented by oral formulations to balance rapid relief and long-term maintenance.The average gross profit margin of this product is 60%.

Long-term management of chronic respiratory diseases is shifting from symptom control toward reducing exacerbations and improving adherence, sustaining expansion of maintenance small molecules in primary care and home settings. Guideline-driven COPD strategies that prioritize long-acting bronchodilation with risk-stratified combinations reinforce the durable role of established small-molecule classes in standardized pathways. Meanwhile, mechanistically differentiated small molecules—such as PDE-inhibition–based approaches with both bronchodilatory and anti-inflammatory profiles—create incremental innovation headroom and new differentiation narratives in large, mature categories.

The segment must balance demonstrable real-world benefit with long-term affordability. Inhaler technique and device heterogeneity can cause outcome variability and adherence gaps, while chronic-use populations are sensitive to tolerability and cumulative treatment burden. At the same time, patent cliffs and generic competition normalize pricing pressure, forcing manufacturers to rebuild cost and supply resilience without compromising quality comparability (delivered dose, particle-size distribution, and device–formulation matching).

Demand is moving from single agents to a dual emphasis on fixed-dose combinations and phenotype/stage-aware regimens. In asthma and COPD maintenance, combination therapy and simplified routines are increasingly used to improve adherence and reduce exacerbation risk. Interest is also rising in small molecules optimized for specific use cases—such as nebulizable options for defined patient groups or profiles better aligned with mucus/airway-inflammatory features. “Felt efficacy, ease of use, and long-term persistence” are becoming the practical product attributes that shape next-generation small-molecule and formulation-engineering competition.

Upstream value is jointly determined by API chemical synthesis and inhalation formulation engineering. On the API side, critical intermediates, catalysts, and high-purity solvent systems drive impurity control and solid-form consistency. On the formulation side, inhaled delivery requirements elevate the importance of excipients and carriers (e.g., DPI carriers and stabilization systems), propellant/valve–seal compatibility for MDIs, and barrier packaging plus device-component interactions. As quality-comparability expectations tighten, upstream competitiveness shifts from “supplying materials” to auditable, traceable, and scale-stable manufacturing systems.

This report delivers a comprehensive overview of the global Small-molecule Respiratory Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Small-molecule Respiratory Drug. The Small-molecule Respiratory Drug market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Small-molecule Respiratory Drug market comprehensively. Regional market sizes by Type, by Application, by Disease, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Small-molecule Respiratory Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Small-molecule Respiratory Drug Market Report

Report Metric	Details
Report Name	Small-molecule Respiratory Drug Market
Accounted market size in 2025	US$ 42153 million
Forecasted market size in 2032	US$ 65244 million
CAGR	6.5%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Bronchodilators Anti-inflammatory Agents Leukotriene Modifiers Others
Segment by Disease	Asthma COPD Others
Segment by Route of Administration	Inhalation Oral Intranasal Topical Others
Segment by Application	Hospital Retail Pharmacy Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	GSK, AstraZeneca, Boehringer Ingelheim, Vertex, Roche, Novartis, Teva, Chiesi, Mylan, Sumitomo Dainippon, Merck
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Disease, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Small-molecule Respiratory Drug companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Small-molecule Respiratory Drug Market growing?

Ans: The Small-molecule Respiratory Drug Market witnessing a CAGR of 6.5% during the forecast period 2026-2032.

What is the Small-molecule Respiratory Drug Market size in 2032?

Ans: The Small-molecule Respiratory Drug Market size in 2032 will be US$ 65244 million.

Who are the main players in the Small-molecule Respiratory Drug Market report?

Ans: The main players in the Small-molecule Respiratory Drug Market are GSK, AstraZeneca, Boehringer Ingelheim, Vertex, Roche, Novartis, Teva, Chiesi, Mylan, Sumitomo Dainippon, Merck

What are the Application segmentation covered in the Small-molecule Respiratory Drug Market report?

Ans: The Applications covered in the Small-molecule Respiratory Drug Market report are Hospital, Retail Pharmacy, Others

What are the Type segmentation covered in the Small-molecule Respiratory Drug Market report?

Ans: The Types covered in the Small-molecule Respiratory Drug Market report are Bronchodilators, Anti-inflammatory Agents, Leukotriene Modifiers, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Small-molecule Respiratory Drug Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Bronchodilators

1.2.3 Anti-inflammatory Agents

1.2.4 Leukotriene Modifiers

1.2.5 Others

1.3 Market by Disease

1.3.1 Global Small-molecule Respiratory Drug Market Size Growth Rate by Disease: 2021 vs 2025 vs 2032

1.3.2 Asthma

1.3.3 COPD

1.3.4 Others

1.4 Market by Route of Administration

1.4.1 Global Small-molecule Respiratory Drug Market Size Growth Rate by Route of Administration: 2021 vs 2025 vs 2032

1.4.2 Inhalation

1.4.3 Oral

1.4.4 Intranasal Topical

1.4.5 Others

1.5 Market by Application

1.5.1 Global Small-molecule Respiratory Drug Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Hospital

1.5.3 Retail Pharmacy

1.5.4 Others

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Small-molecule Respiratory Drug Market Perspective (2021–2032)

2.2 Global Small-molecule Respiratory Drug Growth Trends by Region

2.2.1 Global Small-molecule Respiratory Drug Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Small-molecule Respiratory Drug Historic Market Size by Region (2021–2026)

2.2.3 Small-molecule Respiratory Drug Forecasted Market Size by Region (2027–2032)

2.3 Small-molecule Respiratory Drug Market Dynamics

2.3.1 Small-molecule Respiratory Drug Industry Trends

2.3.2 Small-molecule Respiratory Drug Market Drivers

2.3.3 Small-molecule Respiratory Drug Market Challenges

2.3.4 Small-molecule Respiratory Drug Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Small-molecule Respiratory Drug Players by Revenue

3.1.1 Global Top Small-molecule Respiratory Drug Players by Revenue (2021–2026)

3.1.2 Global Small-molecule Respiratory Drug Revenue Market Share by Players (2021–2026)

3.2 Global Top Small-molecule Respiratory Drug Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Small-molecule Respiratory Drug Revenue

3.4 Global Small-molecule Respiratory Drug Market Concentration Ratio

3.4.1 Global Small-molecule Respiratory Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Small-molecule Respiratory Drug Revenue in 2025

3.5 Global Key Players of Small-molecule Respiratory Drug Head Offices and Areas Served

3.6 Global Key Players of Small-molecule Respiratory Drug, Products and Applications

3.7 Global Key Players of Small-molecule Respiratory Drug, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Small-molecule Respiratory Drug Breakdown Data by Type

4.1 Global Small-molecule Respiratory Drug Historic Market Size by Type (2021–2026)

4.2 Global Small-molecule Respiratory Drug Forecasted Market Size by Type (2027–2032)

5 Small-molecule Respiratory Drug Breakdown Data by Application

5.1 Global Small-molecule Respiratory Drug Historic Market Size by Application (2021–2026)

5.2 Global Small-molecule Respiratory Drug Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Small-molecule Respiratory Drug Market Size (2021–2032)

6.2 North America Small-molecule Respiratory Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Small-molecule Respiratory Drug Market Size by Country (2021–2026)

6.4 North America Small-molecule Respiratory Drug Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Small-molecule Respiratory Drug Market Size (2021–2032)

7.2 Europe Small-molecule Respiratory Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Small-molecule Respiratory Drug Market Size by Country (2021–2026)

7.4 Europe Small-molecule Respiratory Drug Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Small-molecule Respiratory Drug Market Size (2021–2032)

8.2 Asia-Pacific Small-molecule Respiratory Drug Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Small-molecule Respiratory Drug Market Size by Region (2021–2026)

8.4 Asia-Pacific Small-molecule Respiratory Drug Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Small-molecule Respiratory Drug Market Size (2021–2032)

9.2 Latin America Small-molecule Respiratory Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Small-molecule Respiratory Drug Market Size by Country (2021–2026)

9.4 Latin America Small-molecule Respiratory Drug Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Small-molecule Respiratory Drug Market Size (2021–2032)

10.2 Middle East & Africa Small-molecule Respiratory Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Small-molecule Respiratory Drug Market Size by Country (2021–2026)

10.4 Middle East & Africa Small-molecule Respiratory Drug Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 GSK

11.1.1 GSK Company Details

11.1.2 GSK Business Overview

11.1.3 GSK Small-molecule Respiratory Drug Introduction

11.1.4 GSK Revenue in Small-molecule Respiratory Drug Business (2021–2026)

11.1.5 GSK Recent Development

11.2 AstraZeneca

11.2.1 AstraZeneca Company Details

11.2.2 AstraZeneca Business Overview

11.2.3 AstraZeneca Small-molecule Respiratory Drug Introduction

11.2.4 AstraZeneca Revenue in Small-molecule Respiratory Drug Business (2021–2026)

11.2.5 AstraZeneca Recent Development

11.3 Boehringer Ingelheim

11.3.1 Boehringer Ingelheim Company Details

11.3.2 Boehringer Ingelheim Business Overview

11.3.3 Boehringer Ingelheim Small-molecule Respiratory Drug Introduction

11.3.4 Boehringer Ingelheim Revenue in Small-molecule Respiratory Drug Business (2021–2026)

11.3.5 Boehringer Ingelheim Recent Development

11.4 Vertex

11.4.1 Vertex Company Details

11.4.2 Vertex Business Overview

11.4.3 Vertex Small-molecule Respiratory Drug Introduction

11.4.4 Vertex Revenue in Small-molecule Respiratory Drug Business (2021–2026)

11.4.5 Vertex Recent Development

11.5 Roche

11.5.1 Roche Company Details

11.5.2 Roche Business Overview

11.5.3 Roche Small-molecule Respiratory Drug Introduction

11.5.4 Roche Revenue in Small-molecule Respiratory Drug Business (2021–2026)

11.5.5 Roche Recent Development

11.6 Novartis

11.6.1 Novartis Company Details

11.6.2 Novartis Business Overview

11.6.3 Novartis Small-molecule Respiratory Drug Introduction

11.6.4 Novartis Revenue in Small-molecule Respiratory Drug Business (2021–2026)

11.6.5 Novartis Recent Development

11.7 Teva

11.7.1 Teva Company Details

11.7.2 Teva Business Overview

11.7.3 Teva Small-molecule Respiratory Drug Introduction

11.7.4 Teva Revenue in Small-molecule Respiratory Drug Business (2021–2026)

11.7.5 Teva Recent Development

11.8 Chiesi

11.8.1 Chiesi Company Details

11.8.2 Chiesi Business Overview

11.8.3 Chiesi Small-molecule Respiratory Drug Introduction

11.8.4 Chiesi Revenue in Small-molecule Respiratory Drug Business (2021–2026)

11.8.5 Chiesi Recent Development

11.9 Mylan

11.9.1 Mylan Company Details

11.9.2 Mylan Business Overview

11.9.3 Mylan Small-molecule Respiratory Drug Introduction

11.9.4 Mylan Revenue in Small-molecule Respiratory Drug Business (2021–2026)

11.9.5 Mylan Recent Development

11.10 Sumitomo Dainippon

11.10.1 Sumitomo Dainippon Company Details

11.10.2 Sumitomo Dainippon Business Overview

11.10.3 Sumitomo Dainippon Small-molecule Respiratory Drug Introduction

11.10.4 Sumitomo Dainippon Revenue in Small-molecule Respiratory Drug Business (2021–2026)

11.10.5 Sumitomo Dainippon Recent Development

11.11 Merck

11.11.1 Merck Company Details

11.11.2 Merck Business Overview

11.11.3 Merck Small-molecule Respiratory Drug Introduction

11.11.4 Merck Revenue in Small-molecule Respiratory Drug Business (2021–2026)

11.11.5 Merck Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Small-molecule Respiratory Drug Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Bronchodilators

Table 3. Key Players of Anti-inflammatory Agents

Table 4. Key Players of Leukotriene Modifiers

Table 5. Key Players of Others

Table 6. Global Small-molecule Respiratory Drug Market Size Growth Rate by Disease (US$ Million): 2021 vs 2025 vs 2032

Table 7. Key Players of Asthma

Table 8. Key Players of COPD

Table 9. Key Players of Others

Table 10. Global Small-molecule Respiratory Drug Market Size Growth Rate by Route of Administration (US$ Million): 2021 vs 2025 vs 2032

Table 11. Key Players of Inhalation

Table 12. Key Players of Oral

Table 13. Key Players of Intranasal Topical

Table 14. Key Players of Others

Table 15. Global Small-molecule Respiratory Drug Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 16. Global Small-molecule Respiratory Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 17. Global Small-molecule Respiratory Drug Market Size by Region (US$ Million), 2021–2026

Table 18. Global Small-molecule Respiratory Drug Market Share by Region (2021–2026)

Table 19. Global Small-molecule Respiratory Drug Forecasted Market Size by Region (US$ Million), 2027–2032

Table 20. Global Small-molecule Respiratory Drug Market Share by Region (2027–2032)

Table 21. Small-molecule Respiratory Drug Market Trends

Table 22. Small-molecule Respiratory Drug Market Drivers

Table 23. Small-molecule Respiratory Drug Market Challenges

Table 24. Small-molecule Respiratory Drug Market Restraints

Table 25. Global Small-molecule Respiratory Drug Revenue by Players (US$ Million), 2021–2026

Table 26. Global Small-molecule Respiratory Drug Market Share by Players (2021–2026)

Table 27. Global Top Small-molecule Respiratory Drug Players by Tier (Tier 1, Tier 2, and Tier 3), based on Small-molecule Respiratory Drug Revenue, 2025

Table 28. Ranking of Global Top Small-molecule Respiratory Drug Companies by Revenue (US$ Million) in 2025

Table 29. Global 5 Largest Players Market Share by Small-molecule Respiratory Drug Revenue (CR5 and HHI), 2021–2026

Table 30. Global Key Players of Small-molecule Respiratory Drug, Headquarters and Area Served

Table 31. Global Key Players of Small-molecule Respiratory Drug, Products and Applications

Table 32. Global Key Players of Small-molecule Respiratory Drug, Date of General Availability (GA)

Table 33. Mergers and Acquisitions, Expansion Plans

Table 34. Global Small-molecule Respiratory Drug Market Size by Type (US$ Million), 2021–2026

Table 35. Global Small-molecule Respiratory Drug Revenue Market Share by Type (2021–2026)

Table 36. Global Small-molecule Respiratory Drug Forecasted Market Size by Type (US$ Million), 2027–2032

Table 37. Global Small-molecule Respiratory Drug Revenue Market Share by Type (2027–2032)

Table 38. Global Small-molecule Respiratory Drug Market Size by Application (US$ Million), 2021–2026

Table 39. Global Small-molecule Respiratory Drug Revenue Market Share by Application (2021–2026)

Table 40. Global Small-molecule Respiratory Drug Forecasted Market Size by Application (US$ Million), 2027–2032

Table 41. Global Small-molecule Respiratory Drug Revenue Market Share by Application (2027–2032)

Table 42. North America Small-molecule Respiratory Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 43. North America Small-molecule Respiratory Drug Market Size by Country (US$ Million), 2021–2026

Table 44. North America Small-molecule Respiratory Drug Market Size by Country (US$ Million), 2027–2032

Table 45. Europe Small-molecule Respiratory Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 46. Europe Small-molecule Respiratory Drug Market Size by Country (US$ Million), 2021–2026

Table 47. Europe Small-molecule Respiratory Drug Market Size by Country (US$ Million), 2027–2032

Table 48. Asia-Pacific Small-molecule Respiratory Drug Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 49. Asia-Pacific Small-molecule Respiratory Drug Market Size by Region (US$ Million), 2021–2026

Table 50. Asia-Pacific Small-molecule Respiratory Drug Market Size by Region (US$ Million), 2027–2032

Table 51. Latin America Small-molecule Respiratory Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 52. Latin America Small-molecule Respiratory Drug Market Size by Country (US$ Million), 2021–2026

Table 53. Latin America Small-molecule Respiratory Drug Market Size by Country (US$ Million), 2027–2032

Table 54. Middle East & Africa Small-molecule Respiratory Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 55. Middle East & Africa Small-molecule Respiratory Drug Market Size by Country (US$ Million), 2021–2026

Table 56. Middle East & Africa Small-molecule Respiratory Drug Market Size by Country (US$ Million), 2027–2032

Table 57. GSK Company Details

Table 58. GSK Business Overview

Table 59. GSK Small-molecule Respiratory Drug Product

Table 60. GSK Revenue in Small-molecule Respiratory Drug Business (US$ Million), 2021–2026

Table 61. GSK Recent Development

Table 62. AstraZeneca Company Details

Table 63. AstraZeneca Business Overview

Table 64. AstraZeneca Small-molecule Respiratory Drug Product

Table 65. AstraZeneca Revenue in Small-molecule Respiratory Drug Business (US$ Million), 2021–2026

Table 66. AstraZeneca Recent Development

Table 67. Boehringer Ingelheim Company Details

Table 68. Boehringer Ingelheim Business Overview

Table 69. Boehringer Ingelheim Small-molecule Respiratory Drug Product

Table 70. Boehringer Ingelheim Revenue in Small-molecule Respiratory Drug Business (US$ Million), 2021–2026

Table 71. Boehringer Ingelheim Recent Development

Table 72. Vertex Company Details

Table 73. Vertex Business Overview

Table 74. Vertex Small-molecule Respiratory Drug Product

Table 75. Vertex Revenue in Small-molecule Respiratory Drug Business (US$ Million), 2021–2026

Table 76. Vertex Recent Development

Table 77. Roche Company Details

Table 78. Roche Business Overview

Table 79. Roche Small-molecule Respiratory Drug Product

Table 80. Roche Revenue in Small-molecule Respiratory Drug Business (US$ Million), 2021–2026

Table 81. Roche Recent Development

Table 82. Novartis Company Details

Table 83. Novartis Business Overview

Table 84. Novartis Small-molecule Respiratory Drug Product

Table 85. Novartis Revenue in Small-molecule Respiratory Drug Business (US$ Million), 2021–2026

Table 86. Novartis Recent Development

Table 87. Teva Company Details

Table 88. Teva Business Overview

Table 89. Teva Small-molecule Respiratory Drug Product

Table 90. Teva Revenue in Small-molecule Respiratory Drug Business (US$ Million), 2021–2026

Table 91. Teva Recent Development

Table 92. Chiesi Company Details

Table 93. Chiesi Business Overview

Table 94. Chiesi Small-molecule Respiratory Drug Product

Table 95. Chiesi Revenue in Small-molecule Respiratory Drug Business (US$ Million), 2021–2026

Table 96. Chiesi Recent Development

Table 97. Mylan Company Details

Table 98. Mylan Business Overview

Table 99. Mylan Small-molecule Respiratory Drug Product

Table 100. Mylan Revenue in Small-molecule Respiratory Drug Business (US$ Million), 2021–2026

Table 101. Mylan Recent Development

Table 102. Sumitomo Dainippon Company Details

Table 103. Sumitomo Dainippon Business Overview

Table 104. Sumitomo Dainippon Small-molecule Respiratory Drug Product

Table 105. Sumitomo Dainippon Revenue in Small-molecule Respiratory Drug Business (US$ Million), 2021–2026

Table 106. Sumitomo Dainippon Recent Development

Table 107. Merck Company Details

Table 108. Merck Business Overview

Table 109. Merck Small-molecule Respiratory Drug Product

Table 110. Merck Revenue in Small-molecule Respiratory Drug Business (US$ Million), 2021–2026

Table 111. Merck Recent Development

Table 112. Research Programs/Design for This Report

Table 113. Key Data Information from Secondary Sources

Table 114. Key Data Information from Primary Sources

Table 115. Authors List of This Report

List of Figures

Figure 1. Small-molecule Respiratory Drug Picture

Figure 2. Global Small-molecule Respiratory Drug Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Small-molecule Respiratory Drug Market Share by Type: 2025 vs 2032

Figure 4. Bronchodilators Features

Figure 5. Anti-inflammatory Agents Features

Figure 6. Leukotriene Modifiers Features

Figure 7. Others Features

Figure 8. Global Small-molecule Respiratory Drug Market Size Comparison by Disease (US$ Million), 2021–2032

Figure 9. Asthma Features

Figure 10. COPD Features

Figure 11. Others Features

Figure 12. Global Small-molecule Respiratory Drug Market Size Comparison by Route of Administration (US$ Million), 2021–2032

Figure 13. Inhalation Features

Figure 14. Oral Features

Figure 15. Intranasal Topical Features

Figure 16. Others Features

Figure 17. Global Small-molecule Respiratory Drug Market Size by Application (US$ Million), 2021–2032

Figure 18. Global Small-molecule Respiratory Drug Market Share by Application: 2025 vs 2032

Figure 19. Hospital Case Studies

Figure 20. Retail Pharmacy Case Studies

Figure 21. Others Case Studies

Figure 22. Small-molecule Respiratory Drug Report Years Considered

Figure 23. Global Small-molecule Respiratory Drug Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 24. Global Small-molecule Respiratory Drug Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 25. Global Small-molecule Respiratory Drug Market Share by Region: 2025 vs 2032

Figure 26. Global Small-molecule Respiratory Drug Market Share by Players in 2025

Figure 27. Global Small-molecule Respiratory Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 28. The Top 10 and 5 Players Market Share by Small-molecule Respiratory Drug Revenue in 2025

Figure 29. North America Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. North America Small-molecule Respiratory Drug Market Share by Country (2021–2032)

Figure 31. United States Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Canada Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Europe Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Europe Small-molecule Respiratory Drug Market Share by Country (2021–2032)

Figure 35. Germany Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. France Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. U.K. Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Italy Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Russia Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Ireland Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Asia-Pacific Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Asia-Pacific Small-molecule Respiratory Drug Market Share by Region (2021–2032)

Figure 43. China Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Japan Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. South Korea Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Southeast Asia Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. India Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Australia & New Zealand Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Latin America Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. Latin America Small-molecule Respiratory Drug Market Share by Country (2021–2032)

Figure 51. Mexico Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 52. Brazil Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 53. Middle East & Africa Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 54. Middle East & Africa Small-molecule Respiratory Drug Market Share by Country (2021–2032)

Figure 55. Israel Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 56. Saudi Arabia Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 57. UAE Small-molecule Respiratory Drug Market Size YoY Growth (US$ Million), 2021–2032

Figure 58. GSK Revenue Growth Rate in Small-molecule Respiratory Drug Business (2021–2026)

Figure 59. AstraZeneca Revenue Growth Rate in Small-molecule Respiratory Drug Business (2021–2026)

Figure 60. Boehringer Ingelheim Revenue Growth Rate in Small-molecule Respiratory Drug Business (2021–2026)

Figure 61. Vertex Revenue Growth Rate in Small-molecule Respiratory Drug Business (2021–2026)

Figure 62. Roche Revenue Growth Rate in Small-molecule Respiratory Drug Business (2021–2026)

Figure 63. Novartis Revenue Growth Rate in Small-molecule Respiratory Drug Business (2021–2026)

Figure 64. Teva Revenue Growth Rate in Small-molecule Respiratory Drug Business (2021–2026)

Figure 65. Chiesi Revenue Growth Rate in Small-molecule Respiratory Drug Business (2021–2026)

Figure 66. Mylan Revenue Growth Rate in Small-molecule Respiratory Drug Business (2021–2026)

Figure 67. Sumitomo Dainippon Revenue Growth Rate in Small-molecule Respiratory Drug Business (2021–2026)

Figure 68. Merck Revenue Growth Rate in Small-molecule Respiratory Drug Business (2021–2026)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions